Targeting the crosstalk between metabolism and epigenetics to treat liver fibrosis

针对代谢和表观遗传学之间的串扰来治疗肝纤维化

• 批准号: nhmrc : 2001692
• 金额: $ 103.23万
• 依托单位国家: 澳大利亚
• 项目类别: Ideas Grants
• 财政年份: 2021
• 资助国家: 澳大利亚
• 起止时间: 2021-01-01 至 2024-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/targeting-crosstalk-metabolism-liver-fibrosis/1779819
• 关键词: Targeting; crosstalk; between; metabolism; epigenetics

Virtually all liver disease related morbidity and mortality is a consequence of fibrosis that culminates in liver failure or liver cancer. Since anti-fibrotic drugs are not available, new approaches to drug development are required. We have discovered a novel strategy for such drug development by modifying the expression of a specific gene (RARRES1) in a highly targeted manner and thereby interrupting the energy production that is needed by cells to drive fibrosis.

几乎所有与肝脏疾病相关的发病率和死亡率都是纤维化的结果，最终导致肝功能衰竭或肝癌。由于没有抗纤维化药物，因此需要新的药物开发方法。我们已经发现了一种新的药物开发策略，通过以高度靶向的方式修改特定基因(RARRES1)的表达，从而干扰细胞驱动纤维化所需的能量产生。